News

Landos Biopharma to Present at the 38th Annual J.P. Morgan Healthcare Conference

Read More

Landos Biopharma Announces First Patient Dosed in Global Phase 2 Trials of BT-11 in Ulcerative Colitis

Read More

Landos Biopharma Raises $60 Million in Series B Financing

Read More

Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers

Read More

Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11

Read More

Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD

Read More